UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 704

Sortiert nach

Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives

Cancers, 2021-11, Vol.13 (22), p.5722

2021

Link zum Volltext

Verfügbarkeit prüfen

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib

Blood, 2012-01, Vol.119 (2), p.530-539

2012

Link zum Volltext

Verfügbarkeit prüfen

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Nature genetics, 2010-08, Vol.42 (8), p.722-726

2010

Link zum Volltext

Verfügbarkeit prüfen

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

The lancet oncology, 2011-09, Vol.12 (9), p.841-851

2011

Link zum Volltext

Verfügbarkeit prüfen

Comprehensive mutational profiling in advanced systemic mastocytosis

Blood, 2013-10, Vol.122 (14), p.2460-2466

2013

Link zum Volltext

Verfügbarkeit prüfen

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

Haematologica (Roma), 2019-01, Vol.104 (1), p.93-101

2019

Link zum Volltext

Verfügbarkeit prüfen

Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells

Blood, 2007-05, Vol.109 (10), p.4399-4405

2007

Link zum Volltext

Verfügbarkeit prüfen

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

Blood, 2009-12, Vol.114 (24), p.4944-4953

2009

Link zum Volltext

Verfügbarkeit prüfen

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies

Haematologica (Roma), 2014-01, Vol.99 (1), p.7-18

2014

Link zum Volltext

Verfügbarkeit prüfen

Editorial

Forum (Heidelberg), 2020-02, Vol.35 (1), p.1-1

Hochhaus, Andreas

2020

Link zum Volltext

Verfügbarkeit prüfen

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

The Journal of experimental medicine, 2011-10, Vol.208 (11), p.2163-2174

2011

Link zum Volltext

Verfügbarkeit prüfen

Editorial

Forum (Heidelberg), 2020, Vol.35 (1), p.1-1

Hochhaus, Andreas

2020

Link zum Volltext

Verfügbarkeit prüfen

Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia

PloS one, 2016-03, Vol.11 (3), p.e0150632-e0150632

2016

Link zum Volltext

Verfügbarkeit prüfen

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

Haematologica (Roma), 2010-02, Vol.95 (2), p.232-240

2010

Link zum Volltext

Verfügbarkeit prüfen

Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation

Cancers, 2024-04, Vol.16 (7), p.1311

2024

Link zum Volltext

Verfügbarkeit prüfen

Chronische myeloische Leukämie

Die Onkologie, 2023-04, Vol.29 (4), p.305-314

2023

Link zum Volltext

Verfügbarkeit prüfen

Ultra-precise quantification of mRNA targets across a broad dynamic range with nanoreactor beads

PloS one, 2021-03, Vol.16 (3), p.e0242529-e0242529

2021

Link zum Volltext

Verfügbarkeit prüfen

EZH2 in Myeloid Malignancies

Cells (Basel, Switzerland), 2020-07, Vol.9 (7), p.1639

2020

Link zum Volltext

Verfügbarkeit prüfen

Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Blood, 2013-01, Vol.121 (2), p.378-384

2013

Link zum Volltext

Verfügbarkeit prüfen

1 – 25 von 704

Suche als RSS-Feed

Aktive Filter

KollektionRCN full-text journals@Ovid

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(615)
Mit Volltextzugriff
(664)

Publikationsform

Sprache

Englisch
(640)
Deutsch
(64)
Japanisch
(44)
Russisch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(199)
Life Sciences & Biomedicine
(191)
Humans
(183)
Hematology
(136)
Oncology
(93)
Female
(83)
Male
(81)
Middle Aged
(79)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Drug Therapy
(77)
Adult
(74)
Biological And Medical Sciences
(74)
Medical Sciences
(73)
Imatinib Mesylate
(68)
Aged
(66)
Hematologic And Hematopoietic Diseases
(61)
Benzamides
(58)
Leukemias. Malignant Lymphomas. Malignant Reticulosis. Myelofibrosis
(58)
Leukemia, Myelogenous, Chronic, Bcr-Abl Positive - Genetics
(53)
Pyrimidines - Therapeutic Use
(53)
Antineoplastic Agents - Therapeutic Use
(47)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

Blood
(433)
Haematologica
(32)
International Journal Of Radiation Oncology, Biology, Physics
(10)
Seminars In Hematology
(8)
Cancer Research
(7)
Clinical Cancer Research
(7)
Leukemia Research
(6)
Der Onkologe
(5)
Die Onkologie
(5)
Hematology
(5)

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(4)
... seit 90 Tagen
(7)

Menü

Weitere Dienste

Einstellungen

A phase 3, open-label, randomized study of asciminib, a STAMP inhibitor, vs bosutinib in CML after 2 or more prior TKIs

Management of Acute Myeloid Leukemia: Current Treatment Options and Future Perspectives

Low BCR-ABL expression levels in hematopoietic precursor cells enable persistence of chronic myeloid leukemia under imatinib

Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders

Nilotinib versus imatinib for the treatment of patients with newly diagnosed chronic phase, Philadelphia chromosome-positive, chronic myeloid leukaemia: 24-month minimum follow-up of the phase 3 randomised ENESTnd trial

Comprehensive mutational profiling in advanced systemic mastocytosis

Dasatinib or imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: 2-year follow-up from a randomized phase 3 trial (DASISION)

Long-term prognostic significance of early molecular response to imatinib in newly diagnosed chronic myeloid leukemia: an analysis from the International Randomized Study of Interferon and STI571 (IRIS)

Chemoradiotherapy with capecitabine versus fluorouracil for locally advanced rectal cancer: a randomised, multicentre, non-inferiority, phase 3 trial

Incidence, outcomes, and risk factors of pleural effusion in patients receiving dasatinib therapy for Philadelphia chromosome-positive leukemia

Expression of the miR-17-92 polycistron in chronic myeloid leukemia (CML) CD34+ cells

Dasatinib treatment of chronic-phase chronic myeloid leukemia: analysis of responses according to preexisting BCR-ABL mutations

Targeting the phosphoinositide 3-kinase pathway in hematologic malignancies

Desirable performance characteristics for BCR-ABL measurement on an international reporting scale to allow consistent interpretation of individual patient response and comparison of response rates between clinical trials

Editorial

BCL6-mediated repression of p53 is critical for leukemia stem cell survival in chronic myeloid leukemia

Editorial

Polymorphisms of Dectin-1 and TLR2 Predispose to Invasive Fungal Disease in Patients with Acute Myeloid Leukemia

Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib

Synergistic Effects of the RARalpha Agonist Tamibarotene and the Menin Inhibitor Revumenib in Acute Myeloid Leukemia Cells with KMT2A Rearrangement or NPM1 Mutation

Dasatinib induces notable hematologic and cytogenetic responses in chronic-phase chronic myeloid leukemia after failure of imatinib therapy

Chronische myeloische Leukämie

Ultra-precise quantification of mRNA targets across a broad dynamic range with nanoreactor beads

EZH2 in Myeloid Malignancies

Model-based decision rules reduce the risk of molecular relapse after cessation of tyrosine kinase inhibitor therapy in chronic myeloid leukemia

Aktive Filter

Suchergebnisse filtern